Freddy Caldera

1.1k total citations
89 papers, 617 citations indexed

About

Freddy Caldera is a scholar working on Epidemiology, Infectious Diseases and Genetics. According to data from OpenAlex, Freddy Caldera has authored 89 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Epidemiology, 38 papers in Infectious Diseases and 28 papers in Genetics. Recurrent topics in Freddy Caldera's work include Inflammatory Bowel Disease (28 papers), SARS-CoV-2 and COVID-19 Research (20 papers) and Viral gastroenteritis research and epidemiology (19 papers). Freddy Caldera is often cited by papers focused on Inflammatory Bowel Disease (28 papers), SARS-CoV-2 and COVID-19 Research (20 papers) and Viral gastroenteritis research and epidemiology (19 papers). Freddy Caldera collaborates with scholars based in United States, United Kingdom and Germany. Freddy Caldera's co-authors include Mary S. Hayney, Francis A. Farraye, Sumona Saha, Arnold Wald, Ian Grimes, Mark Reichelderfer, Raymond K. Cross, Mario Pirisi, E. Bartoli and Michela Emma Burlone and has published in prestigious journals such as Gastroenterology, Clinical Infectious Diseases and The American Journal of Gastroenterology.

In The Last Decade

Freddy Caldera

75 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Freddy Caldera United States 15 268 262 230 153 130 89 617
Santiago M. C. Lopez United States 10 198 0.7× 389 1.5× 60 0.3× 426 2.8× 29 0.2× 31 846
Manoj Valappil United Kingdom 12 159 0.6× 308 1.2× 32 0.1× 140 0.9× 34 0.3× 27 575
Christel Zufferey Australia 13 300 1.1× 221 0.8× 63 0.3× 264 1.7× 22 0.2× 22 585
Judith J. Ryon United States 17 300 1.1× 606 2.3× 41 0.2× 336 2.2× 161 1.2× 23 898
Amy C Sherman United States 12 352 1.3× 475 1.8× 30 0.1× 131 0.9× 42 0.3× 41 908
Lynette Phillips United States 7 141 0.5× 369 1.4× 34 0.1× 61 0.4× 220 1.7× 17 537
Frederik Trier Møller Denmark 11 240 0.9× 166 0.6× 214 0.9× 96 0.6× 46 0.4× 36 652
José Ángel Rodrigo‐Pendás Spain 12 75 0.3× 472 1.8× 56 0.2× 58 0.4× 45 0.3× 33 579
R. F. Schumacher Italy 10 113 0.4× 148 0.6× 21 0.1× 93 0.6× 80 0.6× 15 373
Anne Krivine France 20 617 2.3× 484 1.8× 18 0.1× 201 1.3× 78 0.6× 42 1.1k

Countries citing papers authored by Freddy Caldera

Since Specialization
Citations

This map shows the geographic impact of Freddy Caldera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Freddy Caldera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Freddy Caldera more than expected).

Fields of papers citing papers by Freddy Caldera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Freddy Caldera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Freddy Caldera. The network helps show where Freddy Caldera may publish in the future.

Co-authorship network of co-authors of Freddy Caldera

This figure shows the co-authorship network connecting the top 25 collaborators of Freddy Caldera. A scholar is included among the top collaborators of Freddy Caldera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Freddy Caldera. Freddy Caldera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cortés, Pedro, Freddy Caldera, Michael F. Picco, et al.. (2024). Utility of a Third Heplisav-B Dose in Patients With Inflammatory Bowel Disease Without Immunity After 2-Dose Heplisav-B Vaccination. The American Journal of Gastroenterology. 119(10). 2079–2085. 5 indexed citations
3.
Farraye, Francis A., et al.. (2024). Inadvertent live vaccine administration in adult patients with inflammatory bowel disease on immunosuppressive therapy. Vaccine. 42(26). 126319–126319. 1 indexed citations
4.
Caldera, Freddy, Siddharth Singh, Jonathan Inselman, et al.. (2024). 549 PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE AT INCREASED RISK FOR COMPLICATIONS OF HERPES ZOSTER. Gastroenterology. 166(5). S–127. 1 indexed citations
5.
Farraye, Francis A., et al.. (2024). High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology. 59(8). 773–779. 2 indexed citations
6.
Alsakarneh, Saqr, et al.. (2024). S1046 Major Adverse Cardiovascular Events in Patients With IBD Taking Anti-TNF vs JAK Inhibitors: A Propensity Matched Cohort Analysis. The American Journal of Gastroenterology. 119(10S). S733–S733.
7.
Caldera, Freddy, Siddharth Singh, Jonathan Inselman, et al.. (2024). Patients With Inflammatory Bowel Disease Are at Increased Risk for Complications of Herpes Zoster. Clinical Gastroenterology and Hepatology. 23(2). 331–340.e2. 3 indexed citations
8.
Caldera, Freddy, Aaron Spaulding, Bijan J. Borah, et al.. (2023). Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 57(11). 1326–1334. 4 indexed citations
9.
Desai, Aakash, Mary S. Hayney, Jana G. Hashash, et al.. (2023). Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study. Inflammatory Bowel Diseases. 30(7). 1094–1102. 2 indexed citations
10.
Beniwal‐Patel, Poonam, António Figueras, Sonya Davé, et al.. (2023). Racial, Ethnic, and Geographic Disparities in Immunization Rates Among Patients With Inflammatory Bowel Disease. Crohn s & Colitis 360. 5(4). otad078–otad078. 1 indexed citations
11.
Caldera, Freddy, Francis A. Farraye, Brian M. Necela, et al.. (2022). Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination. Inflammatory Bowel Diseases. 29(8). 1202–1209. 11 indexed citations
12.
Knutson, Keith L., Sumona Saha, Arnold Wald, et al.. (2022). Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 28(11). 1781–1786. 16 indexed citations
13.
Hayney, Mary S., et al.. (2021). What Gastroenterologists Should Know About COVID-19 Vaccines. Clinical Gastroenterology and Hepatology. 19(4). 657–661. 10 indexed citations
14.
Kochhar, Gursimran, Aakash Desai, Freddy Caldera, et al.. (2021). Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease. Vaccine. 39(30). 4199–4202. 15 indexed citations
15.
Desalermos, Athanasios, Michael Pimienta, Markos Kalligeros, et al.. (2021). Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. 28(9). 1430–1442. 16 indexed citations
16.
17.
Jones, Jeffrey M., J.J. Parrish, Sana M. Salih, et al.. (2018). Methotrexate Reduces DNA Integrity in Sperm From Men With Inflammatory Bowel Disease. Gastroenterology. 154(8). 2064–2067.e3. 26 indexed citations
18.
Caldera, Freddy, Sumona Saha, Arnold Wald, et al.. (2016). Comparing guideline-based care quality for inflammatory bowel disease and rheumatoid arthritis patients within a medical home. Expert Review of Gastroenterology & Hepatology. 10(6). 759–766. 6 indexed citations
19.
Beniwal‐Patel, Poonam, Kristina A. Matkowskyj, & Freddy Caldera. (2015). Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis. Journal of Gastrointestinal and Liver Diseases. 24(3). 274–274. 8 indexed citations
20.
Caldera, Freddy, et al.. (2011). How to avoid common pitfalls with bowel preparation agents. Gastrointestinal Endoscopy. 73(2). 346–348. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Santiago M. C. Lopez Breakdown of academic impact, for papers by Manoj Valappil Breakdown of academic impact, for papers by Christel Zufferey Breakdown of academic impact, for papers by Judith J. Ryon Breakdown of academic impact, for papers by Amy C Sherman Breakdown of academic impact, for papers by Lynette Phillips Breakdown of academic impact, for papers by Frederik Trier Møller Breakdown of academic impact, for papers by José Ángel Rodrigo‐Pendás Breakdown of academic impact, for papers by R. F. Schumacher Breakdown of academic impact, for papers by Anne Krivine
Rankless by CCL
2026